TESARO, Inc. Form 8-K March 14, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 14, 2016

TESARO, Inc.

(Exact name of registrant as specified in its charter)


Delaware 001-35587
(state or other jurisdiction of incorporation) File Number)

27-2249687 (I.R.S. Employer Identification No.)

1000 Winter Street
Suite 3300
Waltham, Massachusetts
(Address of principal executive offices)

02451 (Zip Code)

(339) 970-0900 (Registrant s telephone number, including area code)



Item 8.01 Other Events.

On March 14, 2016, TESARO, Inc. announced its submission of a New Drug Application for intravenous rolapitant to the U.S. Food and Drug Administration. The press release announcing the submission is filed as Exhibit 99.1 to this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press release of TESARO, Inc. dated March 14, 2016 announcing submission of New Drug Application for intravenous rolapitant

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TESARO, Inc.

By: /s/ Joseph L. Farmer

Joseph L. Farmer

Senior Vice President, General Counsel and Secretary

Dated: March 14, 2016

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release of TESARO, Inc. dated March 14, 2016 announcing submission of New Drug Application for intravenous rolapitant.
	4